BIOMAX
30.3.2021 14:02:10 CEST | Business Wire | Press release
Biomax Informatics today announced the development of a novel knowledge management and database solution NeuroCONNECT for EBRAINS, the digital research infrastructure created by the EU-funded Human Brain Project.
NeuroCONNECT allows the semantic integration and management of multimodal brain connectivity information and brain atlases in EBRAINS. The new system will be configured in the NeuroXM™ Brain Science Suite of Biomax. Connectome data will be enriched with metadata from anatomical ontologies, brain atlases and demographic information. This way NeuroCONNECT will become a knowledge hub for all connectome data in the EBRAINS infrastructure.
"We are very proud to have been selected as a partner for EBRAINS and the Human Brain Project, the largest and most influential brain science project in Europe," comments Dr. Klaus Heumann, Chief Executive Officer at Biomax Informatics. “With NeuroCONNECT we will make a valuable contribution to EBRAINS and to all research related to brain disorders and mental health issues.”
EBRAINS was launched in 2019 and will continue to be available to the neuroscience community worldwide also beyond the ten-year life of the Human Brain Project.
End of Press Release
About EBRAINS
EBRAINS is a new digital research infrastructure, created by the EU-funded Human Brain Project, to foster brain-related research and to help translate the latest scientific discoveries into innovation in medicine and industry, for the benefit of patients and society. It draws on cutting-edge neuroscience and offers an extensive range of brain data sets, a multilevel brain atlas, modelling and simulation tools, easy access to high-performance computing resources and to robotics and neuromorphic platforms.
About the NeuroXM™ Brain Science Suite
The NeuroXM™ Brain Science Suite provides comprehensive information from neuroimaging, molecular biology, neuro-genomic data, public ontologies and data sets integrated in a unified knowledge model. The extendible network of interrelated neuroscience concepts gives users a single interface to collect knowledge, focus on specific questions and get a greater return on investments in expensive neurological data.
About Biomax Informatics
Biomax Informatics offers software solutions for better decision-making and optimal knowledge management in the life sciences industry. Using the company’s software, customers can generate added value through the integration of information from their own and public resources, enabling them to achieve a knowledge-based approach for the development of innovative life sciences products. Biomax’s global customers include clinics, companies, and research institutions successful in the fields of research into active substances, diagnostics, fine chemicals, and food and plant products. The company, which was founded in 1997 and currently has 45 members of staff, is headquartered in Planegg near Munich. Further information can be found at www.biomax.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005534/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches Digital Marketplace to Scale AI and Digital Innovation Across Energy15.6.2026 14:15:00 CEST | Press release
Curated marketplace connects energy professionals, developers and partners to discover, deploy and scale trusted AI agents, domain models and digital applications Global energy technology company SLB (NYSE: SLB) today announced the launch of the SLB Digital Marketplace, a curated digital destination designed to help energy companies rapidly discover and deploy specialized AI agents, domain models, skills, tools, data connectors and digital applications within their existing digital environments. The SLB Digital Marketplace extends the company’s open platform strategy to its Tela™ agentic AI assistant by enabling SLB, partners, independent software vendors (ISVs), developers and customers to bring purpose-built digital capabilities to the energy industry through a single, governed channel. All marketplace offerings are certified against SLB standards for security, interoperability and compatibility before listing. The launch comes as the industry moves toward agentic AI — where software
Thales at Eurosatory 2026: Ready today. Ready tomorrow15.6.2026 14:01:00 CEST | Press release
Thales pavilion (stand C247),Parc des Expositions, Paris Nord Villepinte, FranceMonday 15 to Friday 19 June, 2026. As Eurosatory 2026 opens its doors, Thales is pleased to share with you a complete overview of the announcements that will be made during the first day of this international defense and security show. This document centralises all our news, innovations and partnerships, released on June, 15th, 2026 with direct links to the associated press releases: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615204020/en/ Thales at Eurosatory 2026: Ready today. Ready tomorrow.Thales unveils new AI-powered training data analytics platform to enhance military training.Thales launches next-generation 70mm laser-guided rocket dedicated for counter-drone operations.Thales unveils next-generation Bushmaster Mulga Utility Variant.Thales launches RapidStriker, a complete system for protection against drones.Renault Group and Thal
Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery15.6.2026 14:00:00 CEST | Press release
Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory animal care and use. The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity, and operational excellence across its preclinical research and drug discovery activities. Biocytogen’s Boston facility serves as a key hub supporting the company’s expanding portfolio of drug discovery and translational research capabilities. The facility enables a broad range of in vivo studies supporting antibody therapeutics, multispecific antibodies, ADCs, cell therapies, and other innovative biologics programs for pharmaceutical and biotechnology partners worldwide. Through its proprietary BioMice™ platform, Biocytogen has established one of the industry’s most comprehensive collections of genetically engineered disease mo
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 12:00:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission
KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 12:00:00 CEST | Press release
KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom